ADAP insider transaction filings
Adaptimmune Therapeutics PLC — 46 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-09-03. Screen ADAP transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for ADAP between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Adaptimmune Therapeutics PLC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-09-03 | 4 | Wood Gavin — Chief Financial Officer | Sale (S): 96,000 @ $0.01 | EDGAR |
| 2025-08-29 | 4 | Bertrand William C JR — Chief Operating Officer | Sale (S): 207,000 @ $0.01 | EDGAR |
| 2025-08-19 | 4 | Behbahani Ali — Director | Sale (S): 4,828,206 @ $0.01 · Sale (S): 14,671,794 @ $0.01 | EDGAR |
| 2025-07-30 | 4 | EcoR1 Capital, LLC — 10% owner | Sale (S): 33,931,740 @ $0.11 · Sale (S): 2,687,460 @ $0.10 · Sale (S): 27,433,338 @ $0.10 | EDGAR |
| 2025-02-20 | 4 | Brewer Joanna Elizabeth — Chief Scientific Officer | Grant/award (A): 1,612,032 (derivative) @ $0 · Grant/award (A): 1,074,696 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Lunger John — Chief Patient Supply Officer | Grant/award (A): 1,612,032 (derivative) @ $0 · Grant/award (A): 1,074,696 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Piccina Cintia — Chief Commercial Officer | Grant/award (A): 1,612,032 (derivative) @ $0 · Grant/award (A): 1,074,696 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Norry Elliot — Chief Medical Officer | Grant/award (A): 1,612,032 (derivative) @ $0 · Grant/award (A): 1,074,696 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Rawcliffe Adrian — Chief Executive Officer, Director | Grant/award (A): 5,143,248 (derivative) @ $0 · Grant/award (A): 3,428,832 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Bertrand William C JR — Chief Operating Officer | Grant/award (A): 1,612,032 (derivative) @ $0 · Grant/award (A): 1,074,696 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Norry Elliot — Chief Medical Officer | Sale (S): 5,584 @ $0.58 | EDGAR |
| 2025-01-17 | 4 | Lunger John — Chief Patient Supply Officer | Sale (S): 5,584 @ $0.58 | EDGAR |
| 2025-01-17 | 4 | Rawcliffe Adrian — Chief Executive Officer, Director | Sale (S): 30,601 @ $0.58 | EDGAR |
| 2025-01-17 | 4 | Bertrand William C JR — Chief Operating Officer | Sale (S): 5,584 @ $0.58 | EDGAR |
| 2025-01-15 | 4 | Piccina Cintia — Chief Commercial Officer | Sale (S): 12,991 @ $0.57 | EDGAR |
| 2025-01-15 | 4 | Norry Elliot — Chief Medical Officer | Sale (S): 4,268 @ $0.59 · Sale (S): 8,124 @ $0.59 · Sale (S): 9,803 @ $0.57 | EDGAR |
| 2025-01-15 | 4 | Lunger John — Chief Patient Supply Officer | Sale (S): 4,268 @ $0.59 · Sale (S): 5,471 @ $0.59 · Sale (S): 9,803 @ $0.57 | EDGAR |
| 2025-01-15 | 4 | Rawcliffe Adrian — Chief Executive Officer, Director | Sale (S): 12,539 @ $0.59 · Sale (S): 17,934 @ $0.59 · Sale (S): 29,096 @ $0.57 | EDGAR |
| 2025-01-15 | 4 | Bertrand William C JR — Chief Operating Officer | Sale (S): 4,268 @ $0.59 · Sale (S): 5,471 @ $0.59 · Sale (S): 9,803 @ $0.57 | EDGAR |
| 2024-07-01 | 4 | Hegde Priti — Director | Grant/award (A): 1,144,686 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Furey John — Director | Grant/award (A): 660,000 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Behbahani Ali — Director | Grant/award (A): 1,144,686 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Menzel Garry E — Director | Grant/award (A): 1,121,604 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Alleva Lawrence M — Director | Grant/award (A): 1,213,926 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Allen Andrew R — Director | Grant/award (A): 660,000 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Hege Kristen — Director | Grant/award (A): 660,000 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | MOTT DAVID M — Director | Grant/award (A): 1,583,214 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Piccina Cintia — Chief Commercial Officer | Sale (S): 24,531 @ $0.93 | EDGAR |
| 2024-03-18 | 4 | Piccina Cintia — Chief Commercial Officer | Grant/award (A): 5,088,864 (derivative) @ $0 · Grant/award (A): 1,130,832 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Norry Elliot — Chief Medical Officer | Sale (S): 2,287 @ $0.79 · Sale (S): 5,309 @ $0.67 · Sale (S): 12,967 @ $0.67 | EDGAR |
| 2024-01-17 | 4 | Lunger John — Chief Patient Supply Officer | Sale (S): 4,681 @ $0.79 · Sale (S): 5,309 @ $0.67 · Sale (S): 12,805 @ $0.67 | EDGAR |
| 2024-01-17 | 4 | Lunger John — Chief Patient Supply Officer | Grant/award (A): 2,544,432 (derivative) @ $0 · Grant/award (A): 565,416 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Brewer Joanna Elizabeth — Chief Scientific Officer | Grant/award (A): 2,544,432 (derivative) @ $0 · Grant/award (A): 565,416 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | TAYTON-MARTIN HELEN KATRINA — Chief Business & Strgy Officer | Grant/award (A): 2,544,432 (derivative) @ $0 · Grant/award (A): 565,416 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Norry Elliot — Chief Medical Officer | Grant/award (A): 2,544,432 (derivative) @ $0 · Grant/award (A): 565,416 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Behbahani Ali — Director | Grant/award (A): 40,950 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Wood Gavin — Chief Financial Officer | Grant/award (A): 2,544,432 (derivative) @ $0 · Grant/award (A): 565,416 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Rawcliffe Adrian — Chief Executive Officer, Director | Sale (S): 9,304 @ $0.79 · Sale (S): 30,080 @ $0.67 | EDGAR |
| 2024-01-17 | 4 | Rawcliffe Adrian — Chief Executive Officer, Director | Grant/award (A): 7,633,296 (derivative) @ $0 · Grant/award (A): 1,696,272 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Hege Kristen — Director | Grant/award (A): 81,906 (derivative) @ $0 | EDGAR |
| 2024-01-17 | 4 | Bertrand William C JR — Chief Operating Officer | Sale (S): 4,681 @ $0.79 · Sale (S): 5,309 @ $0.67 · Sale (S): 13,599 @ $0.67 | EDGAR |
| 2024-01-17 | 4 | Bertrand William C JR — Chief Operating Officer | Grant/award (A): 2,544,432 (derivative) @ $0 · Grant/award (A): 565,416 (derivative) @ $0 | EDGAR |
| 2024-01-12 | 4 | Lunger John — Chief Patient Supply Officer | Sale (S): 4,009 @ $0.84 · Sale (S): 5,220 @ $0.85 | EDGAR |
| 2024-01-12 | 4 | Norry Elliot — Chief Medical Officer | Sale (S): 4,009 @ $0.84 · Sale (S): 7,799 @ $0.85 | EDGAR |
| 2024-01-12 | 4 | Rawcliffe Adrian — Chief Executive Officer, Director | Sale (S): 11,945 @ $0.84 · Sale (S): 17,257 @ $0.85 | EDGAR |
| 2024-01-12 | 4 | Bertrand William C JR — Chief Operating Officer | Sale (S): 4,009 @ $0.84 · Sale (S): 5,220 @ $0.85 | EDGAR |
Recent 8-K events — Adaptimmune Therapeutics PLC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-10-20 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-26 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-09-12 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-09-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-14 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-31 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ADAP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →